Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.5. rezultāts no 100.
9. lappuse
... person includes individ- uals , partnerships , corporations , and associations . ( f ) The definitions and interpreta- tions of terms contained in section 201 of the act shall be applicable to such terms when used in the regulations in ...
... person includes individ- uals , partnerships , corporations , and associations . ( f ) The definitions and interpreta- tions of terms contained in section 201 of the act shall be applicable to such terms when used in the regulations in ...
13. lappuse
... person . Any interested person may file a petition seeking such exemption , which petition may be pursuant to part 10 of this chapter , or in the form of a supplement to an approved new drug application . ( c ) New drug status of drugs ...
... person . Any interested person may file a petition seeking such exemption , which petition may be pursuant to part 10 of this chapter , or in the form of a supplement to an approved new drug application . ( c ) New drug status of drugs ...
20. lappuse
... the Commis- sioner on his own initiative or on the petition of any interested person , pur- suant to part 10 of this chapter . Prior to issuance of such a proposal , the ap- plicant 20 §310.303 21 CFR Ch . I ( 4198 Edition )
... the Commis- sioner on his own initiative or on the petition of any interested person , pur- suant to part 10 of this chapter . Prior to issuance of such a proposal , the ap- plicant 20 §310.303 21 CFR Ch . I ( 4198 Edition )
21. lappuse
... person subject to the reporting requirements of para- graph ( c ) of this section shall also de- velop written ... person's ability to conduct normal life functions . Life - threatening adverse drug experi- ence . Any adverse drug ...
... person subject to the reporting requirements of para- graph ( c ) of this section shall also de- velop written ... person's ability to conduct normal life functions . Life - threatening adverse drug experi- ence . Any adverse drug ...
22. lappuse
... person whose name appears on the label . Each report shall be accompanied by a copy of the current labeling for the drug product . ( ii ) A person identified in paragraph ( c ) ( 1 ) ( i ) of this section is not required to submit a 15 ...
... person whose name appears on the label . Each report shall be accompanied by a copy of the current labeling for the drug product . ( ii ) A person identified in paragraph ( c ) ( 1 ) ( i ) of this section is not required to submit a 15 ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning